Predictors of Fecal Elastase Testing Completion in Outpatient and Inpatient Settings: A Single Center Retrospective Analysis

OBJECTIVES: To characterize completion of fecal elastase-1 (FE-1) testing, identify clinical contexts associated with abnormal results, evaluate downstream diagnostic and treatment events, and determine the clinical significance of non-completion. METHODS: We conducted a retrospective cohort study of adults with FE-1 orders from 2017 through 2022 in a large integrated health system. Orders placed within 30 days were consolidated into diagnostic episodes. Completion required a linked specimen with a reported result. We evaluated pre-order clinical contexts and one-year outcomes and performed a weighted manual chart review of 200 unique patients with non-completed episodes sampled from four downstream pathway strata. RESULTS: Among 23,422 diagnostic episodes, 11,834 (50.5%) were completed. FE-1 ≤200 µg/g occurred in 20.4% of interpretable results and varied by clinical context: 13.7% with irritable bowel syndrome, 21.2% with chronic diarrhea, 38.3% with chronic pancreatitis, 60.1% with pancreatic cancer, and 79.5% after pancreatic surgery. Initial completion was associated with higher odds of new exocrine pancreatic insufficiency diagnosis (adjusted odds ratio, 2.27; 95% confidence interval, 1.91-2.70) and pancreatic enzyme replacement therapy initiation (adjusted odds ratio, 2.20; 95% confidence interval, 1.89-2.55), whereas non-completion was associated with more repeat FE-1 testing. Among eligible unique non-completers, weighted chart review classified 66.9% as probable missed diagnostic follow-through based on available documentation; failure to submit or return the specimen (60.1%) and specimen-processing problems (20.4%) predominated. CONCLUSIONS: FE-1 completion was modestly associated with measured pre-order factors, while abnormal results varied substantially by clinical context. Specimen return, processing, and closed-loop follow-up represent potential targets for improving evaluation of exocrine pancreatic insufficiency.

Authors

Institutions

Publication Details

Journal
Pancreas
Published
2026-11-16
DOI
https://doi.org/10.1097/mpa.0000000000002738
Primary Topic
Pancreatitis Pathology and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Predictors of Fecal Elastase Testing Completion in Outpatient and Inpatient Settings: A Single Center Retrospective Analysis

Kunzah A. Syed, Ridhima Kaul, Arjun Chatterjee, Mitchell L. Ramsey et al.
2 links
Pancreas
Pancreatitis Pathology and Treatment
article

Predictors of Fecal Elastase Testing Completion in Outpatient and Inpatient Settings: A Single Center Retrospective Analysis

Kunzah A. Syed, Ridhima Kaul, Arjun Chatterjee, Mitchell L. Ramsey, Abdullah Allaoa, John McMichael, Tyler Stevens, Stephen Firkins, Hassan Siddiki, Syed Mohiuddin, Renan Prado, Georgios Papachristou, Pavan Krishna Kottachalla, FNU Vikash, Ishani Patel, Prabhleen Chahal
article en

Abstract

OBJECTIVES: To characterize completion of fecal elastase-1 (FE-1) testing, identify clinical contexts associated with abnormal results, evaluate downstream diagnostic and treatment events, and determine the clinical significance of non-completion. METHODS: We conducted a retrospective cohort study of adults with FE-1 orders from 2017 through 2022 in a large integrated health system. Orders placed within 30 days were consolidated into diagnostic episodes. Completion required a linked specimen with a reported result. We evaluated pre-order clinical contexts and one-year outcomes and performed a weighted manual chart review of 200 unique patients with non-completed episodes sampled from four downstream pathway strata. RESULTS: Among 23,422 diagnostic episodes, 11,834 (50.5%) were completed. FE-1 ≤200 µg/g occurred in 20.4% of interpretable results and varied by clinical context: 13.7% with irritable bowel syndrome, 21.2% with chronic diarrhea, 38.3% with chronic pancreatitis, 60.1% with pancreatic cancer, and 79.5% after pancreatic surgery. Initial completion was associated with higher odds of new exocrine pancreatic insufficiency diagnosis (adjusted odds ratio, 2.27; 95% confidence interval, 1.91-2.70) and pancreatic enzyme replacement therapy initiation (adjusted odds ratio, 2.20; 95% confidence interval, 1.89-2.55), whereas non-completion was associated with more repeat FE-1 testing. Among eligible unique non-completers, weighted chart review classified 66.9% as probable missed diagnostic follow-through based on available documentation; failure to submit or return the specimen (60.1%) and specimen-processing problems (20.4%) predominated. CONCLUSIONS: FE-1 completion was modestly associated with measured pre-order factors, while abnormal results varied substantially by clinical context. Specimen return, processing, and closed-loop follow-up represent potential targets for improving evaluation of exocrine pancreatic insufficiency.

Pancreas
Cleveland Clinic (US), The University of Texas System (US), The University of Texas at San Antonio Health Science Center (US), The Ohio State University Wexner Medical Center (US)
Good health and well-being
Pancreatitis Pathology and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon